Vax for rare, deadly mosquito-borne viruses shows promise in trial

10

Washington, May 13 | A vaccine for eastern equine encephalitis virus (EEEV), western equine encephalitis virus (WEEV), and Venezuelan equine encephalitis virus (VEEV) was found to be safe, well-tolerated and induced a neutralising antibody response in adult volunteers, according to newly published results from a Phase 1 clinical trial.

The vaccine candidate was developed by scientists at the US National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC), part of the National Institutes of Health.

EEEV, WEEV and VEEV are spread to humans through the bites of infected mosquitoes.

Infections from these diseases in humans are rare but can lead to flu-like symptoms and, in some cases, severe neurological damage or death.

However, under certain laboratory conditions, the viruses can transmit through the air by aerosol droplets and cause infection in humans and are therefore classified as priority pathogens, potential biological agents that pose a risk to national security and public health.

NIAID Director Anthony Fauci, and team have highlighted the possible utility of a vaccine for EEEV for people at high occupational risk of contracting the disease, including members of the military and laboratory workers.

According to researchers, horses are also susceptible to infection, but horses cannot transmit the viruses directly to humans.

The viruses have caused recurrent, small outbreaks in North, Central and South America, including an EEEV outbreak in 2019 in the northeastern United States that led to 38 confirmed cases and 15 deaths.

In the study appearing in The Lancet Infectious Diseases, VRC researchers designed a virus-like particle (VLP) vaccine candidate (abbreviated WEVEE) that uses proteins from the outer shells of the EEE, WEE and VEE viruses to prompt an immune response. VLPs do not contain the genetic material that the viruses need to replicate inside cells, so VLPs cannot cause infection.

For the Phase 1 clinical trial, 30 healthy adult volunteers ages 18 to 50 years received varying doses of the WEVEE vaccine (6, 30 or 60 micrograms) by intramuscular injection.

Participants then returned to receive the same dose as a boost eight weeks later. Some participants also received a formulation of the experimental vaccine that contained an alum adjuvant added to increase immune responses.

The team reported that the vaccine was safe, well-tolerated and induced durable immune responses against all three viruses.

The highest neutralising antibody response was observed in participants who received the 30-microgram dose with adjuvant. The authors note that the findings support further clinical evaluation of the vaccine candidate.

NIAID has approved a commercialisation licence for the advanced development of the WEVEE vaccine candidate to the life sciences company Emergent BioSolutions in Maryland, US.

Source: IANS

Next Story

Weekly Technical Share Market Outlook

Weekly Technical Share Market Outlook

The Indian market recovered sharply on the last trading day amid the weekend after a continuous fall. Market has managed to halt above 16000 Nifty levels after continuous losing streak. Index reacted violently, grasping Indian as well as global factors throughout the week. Simultaneously, Inflation is catching up and profit margins are taking a hit.

 

Sensex advanced 1532 points or 2.90 percent while Nifty gained 484 points or 3.07 percent in a week. Simultaneously, Bank nifty has overcome bear’s dominance ending the session with 3.49 percent gain. Sectorally,Nifty Metal saw the highest gains of 7.40 percent followed by the Realty and Auto added over 4% gain. On the flip side Nifty IT tumbled 2.82 percent on weekly basis. Midcap and Small Cap measures rising nearly 2 percent as well.

In Nifty stock, EICHERMOT gained 11.31% while TECHM lost 5.98% on a weekly basis. INDIA VIX closes at 23.10 suggests volatility driven market is going to remain intact. Coming to the OI Data, on the call side highest OI witnessed at 17000 Nifty followed by 16800 Nifty strike price while on the put side, the highest OI was at 16000 Nifty followed by 15800 Nifty strike price. Technically, Nifty has formed a Tweezer Bottom type pattern in the weekly chart suggesting a short term buying rally may drive the market until monthly expiry. On the daily chart, price has rebounded from the lower Bollinger band as well.

Momentum indicators MACD & Stochastic were trading with a positive crossover & reversed from oversold zone. However, Index is still struggling to get the support of 50 Simple Moving Average in daily chart. Short term investors and traders are advised to work with option strategies to neutralize the volatility. Overall, Nifty is having support at 15700 mark while on the upside 16700 followed by 16500 may act as an immediate resistance. While Bank nifty has support around 32500 while resistance is placed at 36000 on weekly chart.

Sumeet Bagadia
Executive Director
Choice Broking

Source: Choice India

LEAVE A REPLY

Please enter your comment!
Please enter your name here